Tanios Bekaii Saab
Tanios Bekaii Saab
Mayo Clinic Cancer Center
Verified email at
Cited by
Cited by
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet 395 (10241), 1907-1918, 2020
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open …
A Wang-Gillam, CP Li, G Bodoky, A Dean, YS Shan, G Jameson, ...
The Lancet 387 (10018), 545-557, 2016
Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma
M Javle, M Lowery, RT Shroff, KH Weiss, C Springfeld, MJ Borad, ...
Journal of Clinical Oncology 36 (3), 276, 2018
Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner
TA Mace, Z Ameen, A Collins, S Wojcik, M Mair, GS Young, JR Fuchs, ...
Cancer research 73 (10), 3007-3018, 2013
Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology …
MHG Katz, Q Shi, SA Ahmad, JM Herman, RW Marsh, E Collisson, ...
JAMA surgery 151 (8), e161137-e161137, 2016
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
TA Mace, R Shakya, JR Pitarresi, B Swanson, CW McQuinn, S Loftus, ...
Gut 67 (2), 320-332, 2018
Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers
T Bekaii-Saab, MA Phelps, X Li, M Saji, L Goff, JSW Kauh, BH O'Neil, ...
Journal of clinical oncology 29 (17), 2357, 2011
Pain, depression, and fatigue: loneliness as a longitudinal risk factor.
LM Jaremka, RR Andridge, CP Fagundes, CM Alfano, SP Povoski, ...
Health Psychology 33 (9), 948, 2014
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study
VK Morris, ME Salem, H Nimeiri, S Iqbal, P Singh, K Ciombor, B Polite, ...
The Lancet Oncology 18 (4), 446-453, 2017
Biliary cancer: Utility of next‐generation sequencing for clinical management
M Javle, T Bekaii‐Saab, A Jain, Y Wang, RK Kelley, K Wang, HC Kang, ...
Cancer 122 (24), 3838-3847, 2016
Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline
RT Shroff, EB Kennedy, M Bachini, T Bekaii-Saab, C Crane, J Edeline, ...
Journal of Clinical Oncology 37 (12), 1015-1027, 2019
Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial
RT Shroff, MM Javle, L Xiao, AO Kaseb, GR Varadhachary, RA Wolff, ...
JAMA oncology 5 (6), 824-830, 2019
Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas
M Blazer, C Wu, RM Goldberg, G Phillips, C Schmidt, P Muscarella, ...
Annals of surgical oncology 22 (4), 1153-1159, 2015
Colon cancer, version 3.2014
AB Benson, AP Venook, T Bekaii-Saab, E Chan, YJ Chen, HS Cooper, ...
Journal of the National Comprehensive Cancer Network 12 (7), 1028-1059, 2014
Rectal cancer, version 2.2015
AB Benson, AP Venook, T Bekaii-Saab, E Chan, YJ Chen, HS Cooper, ...
Journal of the National Comprehensive Cancer Network 13 (6), 719-728, 2015
Gastric cancer
JA Ajani, JS Barthel, T Bekaii-Saab, DJ Bentrem, TA D'Amico, P Das, ...
Journal of the National Comprehensive Cancer Network 8 (4), 378-409, 2010
A multi‐institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer
EJ Kim, E Ben‐Josef, JM Herman, T Bekaii‐Saab, LA Dawson, KA Griffith, ...
Cancer 119 (15), 2692-2700, 2013
Rectal cancer
AB Benson, T Bekaii-Saab, E Chan, YJ Chen, MA Choti, HS Cooper, ...
Journal of the National Comprehensive Cancer Network 10 (12), 1528-1564, 2012
Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis
QP Janssen, S Buettner, M Suker, BR Beumer, P Addeo, P Bachellier, ...
JNCI: Journal of the National Cancer Institute 111 (8), 782-794, 2019
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
TS Bekaii-Saab, FS Ou, DH Ahn, PM Boland, KK Ciombor, EN Heying, ...
The lancet oncology 20 (8), 1070-1082, 2019
The system can't perform the operation now. Try again later.
Articles 1–20